Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%

SOLIGENIX, INC.

SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.
7 of 8 patients reported benefit; 1 patient's skin ulcer resolved; no treatment-related adverse events.
Improvement sustained at Week 8 (32%) despite stopping treatment at Week 4; Otezla continuous dosing had 41%.
Company plans reformulation for home subcutaneous injection and a placebo-controlled Phase 2 study.
Behçet's Disease affects ~18,000 in US; SGX945 well-tolerated with no GI side effects vs Otezla.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.